- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00768599
A Study of Econazole Foam 1% in Athlete's Foot
December 5, 2012 updated by: AmDerma
A Multi-Center Randomized, Evaluator-Blinded, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1%, Econazole Nitrate 1% Cream, and Foam Vehicle in Subjects With Tinea Pedis
This is a 6-week clinical study (4 weeks of treatment, once per day, plus a 2-week follow-up period) of a topical foam to treat athlete's foot.
The active ingredient in the foam -- econazole nitrate 1% -- is the same active pharmaceutical ingredient in a cream that your doctor can currently prescribe to treat athlete's foot.
This study will help to understand if the foam works the same as the cream to treat athlete's foot.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Treating athlete's foot with a cream can leave a greasy, wet feeling on the foot that is uncomfortable to the user and messy on clothing and foot wear.
A foam formulation that spreads easily and rubs-in easily that is as effective as the (reference) cream formulation in treating athlete's foot would be a benefit to the user.
This study is designed to substantiate a clinical bridge between econazole nitrate foam 1% and econazole nitrate cream 1% based on clinical outcome, safety, and pharmacokinetic data.
The study is (foam) vehicle-controlled and is randomized 1 to 1 to 1 (foam:cream:vehicle).
Study Type
Interventional
Enrollment (Actual)
135
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Stacy Smith, MD
-
-
Michigan
-
Clinton Township, Michigan, United States, 48038
- Daniel Stewart, DO
-
-
Minnesota
-
Fridley, Minnesota, United States, 55432
- Steven Kempers, MD
-
-
Tennessee
-
Nashville, Tennessee, United States, 37215
- Michael Gold, MD
-
-
Texas
-
Austin, Texas, United States, 78759
- Michael Jarratt, MD
-
-
Utah
-
Salt Lake City, Utah, United States, 84124
- Leonard Swinyer, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be at least 18 years or age and of either sex.
- Has a clinical diagnosis of tinea pedis with at least i) moderate scaling(interdigital and/or moccasin) and ii) mild erythema (interdigital only).
- Be willing to give informed consent.
- Be willing and able to give informed consent.
- Has microscopic evidence (positive KOH) of the presence of fungi. Evaluable subjects must have a positive KOH and a fungal culture positive for a dermatophyte at Baseline. Subjects with a positive KOH may be entered into the study pending the results of the fungal culture.
- Be in good health and free of any disease or physical condition which might, in the investigator's opinion, expose the subject to an unacceptable risk by study participation.
- Women of childbearing potential must have a negative urine pregnancy test and agree to use an effective, non-prohibited form of birth control for the duration of the study (abstinence, stabilized on oral contraceptives for at least two months, implant, injection, IUD, patch, NuvaRing, condom and spermicidal or diaphragm and spermicidal).
Exclusion Criteria:
- Is nursing or planning a pregnancy during the study.
- Has used topical antifungal or corticosteroid therapy or systemic antibacterial therapy within 30 days prior to the start of the study.
- Has received systemic antifungal therapy within 12 weeks prior to the start of the study medication.
- Has a history of diabetes mellitus or is immunocompromised (due to disease, e.g., HIV, or medications).
- Has concurrent tinea infection (in the opinion of the investigator). However, concurrent onychomycosis is allowed.
- Has any other skin disease which might interfere with the evaluation of tinea pedis.
- Is currently enrolled in an investigational drug or device study.
- Has received an investigational drug or treatment with an investigational device within 30 days prior to entering this study
- Is unreliable, including subjects with a history of drug or alcohol abuse.
- Has known hypersensitivity to any of the components of the study medications.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Econazole Nitrate Cream 1%
|
Topical cream, applied once daily for 4 weeks.
Other Names:
|
Experimental: 2
Econazole Nitrate Foam 1%
|
Topical foam, applied once daily for 4 weeks.
Other Names:
|
Placebo Comparator: 3
Vehicle Foam
|
Topical foam, applied once daily for 4 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Cure Rate: Interdigital Disease
Time Frame: Day 43
|
A negative KOH and negative culture and no evidence of clinical disease as indicated by scores of 0 for each sign and symptom at Day 43.
|
Day 43
|
Complete Cure Rate: Moccasin Disease
Time Frame: 43 Days
|
A negative KOH and negative culture and no evidence of clinical disease as indicated by scores of 0 for each sign and symptom at Day 43.
|
43 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effective Treatment: Interdigital Disease
Time Frame: 43
|
Negative KOH, negative fungal culture, no or mild (a score of 0 or 1) erythema and/or scaling with all other signs or symptoms being absent (score = 0) at Day 43 (Week6).
|
43
|
Effective Treatment: Mocassin Disease
Time Frame: 43
|
Negative KOH, negative fungal culture, no or mild (a score of 0 or 1) erythema and/or scaling with all other signs or symptoms being absent (score = 0) at Day 43 (Week6).
|
43
|
Mycological Cure: Interdigital Disease
Time Frame: 43
|
Negative KOH and negative fungal culture at Day 43
|
43
|
Mycological Cure: Mocassin Disease
Time Frame: 43
|
Negative KOH and negative fungal culture at Day 43
|
43
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Primary Completion (Actual)
September 1, 2008
Study Completion (Actual)
October 1, 2008
Study Registration Dates
First Submitted
October 7, 2008
First Submitted That Met QC Criteria
October 7, 2008
First Posted (Estimate)
October 8, 2008
Study Record Updates
Last Update Posted (Estimate)
January 9, 2013
Last Update Submitted That Met QC Criteria
December 5, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Foot Diseases
- Bacterial Infections and Mycoses
- Skin Diseases, Infectious
- Mycoses
- Skin Manifestations
- Dermatomycoses
- Foot Dermatoses
- Pruritus
- Tinea
- Tinea Pedis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Econazole
Other Study ID Numbers
- D79-2902-07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tinea Pedis
-
National institute of SiddhaCompletedTinea Infections Such as Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Mannum, Tinea Barbae, Tinea Capitis Are StudiedIndia
-
Taro Pharmaceuticals USATerminated
-
DermBiont, Inc.TerminatedInterdigital Tinea PedisDominican Republic
-
AmDermaAmDerma Pharmaceuticals, LLCCompletedInterdigital Tinea PedisUnited States
-
Ahmed A. H. AbdellatifUnknownFoot Infection Tinea PedisEgypt
-
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences...CompletedOnychomycosis/Onycholysis and Tinea PedisUnited States
-
Tinea PharmaceuticalsCompletedTinea Pedis | Tinea Cruris | Tinea CorporisUnited States, Puerto Rico, El Salvador, Belize, Honduras
-
Therapeutics, Inc.RecruitingTinea Pedis | Tinea CrurisUnited States
-
Bausch & Lomb IncorporatedBausch Health Americas, Inc.CompletedTinea Pedis | Tinea CrurisUnited States
-
Bausch Health Americas, Inc.CompletedTinea Pedis | Tinea CrurisDominican Republic, Honduras
Clinical Trials on Econazole Nitrate Cream 1%
-
AmDermaAmDerma Pharmaceuticals, LLCCompletedTinea Pedis | Athlete's FootUnited States
-
Aziende Chimiche Riunite Angelini Francesco S.p.ACross Research S.A.Completed
-
Taro Pharmaceuticals USACompleted
-
Mylan Inc.DPT Laboratories, Ltd.Completed
-
Minia UniversityCompleted
-
AmDermaAmDerma Pharmaceuticals, LLCCompletedTinea Pedis | Athlete's FootUnited States
-
Padagis LLCCompletedVulvovaginal CandidiasisUnited States
-
Aziende Chimiche Riunite Angelini Francesco S.p.ACross Research S.A.CompletedHealthy WomenSwitzerland
-
Jamaica Hospital Medical CenterJohnson & JohnsonUnknownTinea Pedis | Athlete's Foot | Foot Fungus | RingwormUnited States
-
AmDermaAmDerma Pharmaceuticals, LLCCompletedInterdigital Tinea PedisUnited States